预防膀胱癌患者发生静脉血栓栓塞的研究进展

doi:10.3760/cma.j.issn.1007-1245.2023.15.001

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (15): 2073-2076.DOI: 10.3760/cma.j.issn.1007-1245.2023.15.001

• 医学新进展 • 下一篇

预防膀胱癌患者发生静脉血栓栓塞的研究进展

徐希^1,2 李向阳² 张波² 向远刚² 阳攀² 张振声¹ 许传亮¹

¹海军军医大学第一附属医院泌尿外科，上海　200433；²31635部队保障部，桂林　510004

收稿日期:2023-02-28 出版日期:2023-08-01 发布日期:2023-08-28
通讯作者: 张振声，Email：13761178177@163.com
基金资助:
上海市卫生健康委员会科研课题（201940177）；海军军医大学“深蓝”人才工程“远航”人才计划（2021）

Advances on prevention of venous thromboembolism in patients with bladder cancer

Xu Xi^1,2, Li Xiangyang², Zhang Bo², Xiang Yuangang², Yang Pan², Zhang Zhensheng¹, Xu Chuanliang¹

¹Department of Urology, First Affiliated Hospital, Naval Medical University, Shanghai 200433, China; ²Support Department, Unit 31635 of PLA, Guilin 510004, China

Received:2023-02-28 Online:2023-08-01 Published:2023-08-28
Contact: Zhang Zhensheng, Email: 13761178177@163.com
Supported by:
Scientific Research Project of Shanghai Municipal Health Commission (201940177); "Deep Blue" Talent Project "Voyage" Talent Plan of Naval Medical University (2021)

摘要/Abstract

摘要：

众所周知，癌症是发生血栓的一个重要危险因素。静脉血栓栓塞（VTE）包括肺栓塞和深静脉血栓形成，是常见的由恶性肿瘤引起的血管疾病。膀胱癌患者在诊断后5年内发生VTE的概率约8%，明显高于其他恶性肿瘤。VTE发病率与患者的特定特征相关，如年龄、疾病阶段和治疗方式等，而不仅取决于是否手术。膀胱癌患者的血栓防治并非没有风险，但可以为疾病预后提供指导和决策。

关键词:

血栓, 静脉血栓栓塞, 膀胱癌, 治疗方式, 预防, 进展

Abstract:

As we all know, cancer is an important risk factor for thrombosis. Venous thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis, is the common vascular disease caused by malignant tumors. Studies have shown that patients with bladder cancer have almost 8% probability of developing VTE within 5 years of diagnosis, which is higher than other malignant tumors. The incidence of VTE is associated with specific features, such as age, disease stage, and treatment, but not just with whether surgery. Although the therapy has risks, it can provide guidance and decision for the prognosis in bladder cancer patients.

Key words:

Thrombosis, Venous thromboembolism, Bladder cancer, Treatment, Prevention, Progress

徐希李向阳张波向远刚阳攀张振声许传亮.

预防膀胱癌患者发生静脉血栓栓塞的研究进展 [J]. 国际医药卫生导报, 2023, 29(15): 2073-2076.

Xu Xi, Li Xiangyang, Zhang Bo, Xiang Yuangang, Yang Pan, Zhang Zhensheng, Xu Chuanliang.

Advances on prevention of venous thromboembolism in patients with bladder cancer [J]. International Medicine and Health Guidance News, 2023, 29(15): 2073-2076.

参考文献

[1] Yamashita Y, Morimoto T, Kimura T. Venous thromboembolism: recent advancement and future perspective[J]. J Cardiol,2022,79(1):79-89.DOI:10.1016/j.jjcc.2021.08.026.
[2] Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism[J].Nat Rev Dis Primers,2022,8(1):11.DOI:10.1038/s41572-022- 00336-y.
[3] Sun MY, Bhaskar SMM. Venous thromboembolism in cancer patients undergoing chemotherapy: a systematic review and meta-analysis[J].Diagnostics (Basel),2022,12(12):2954.DOI:10.3390/diagnostics12122954.
[4] Robinson CM, Poon BPK, Kano Y, et al. A hypoxia-inducible HIF1-GAL3ST1-sulfatide axis enhances ccRCC immune evasion via increased tumor cell-platelet binding[J].Mol Cancer Res,2019,17(11):2306-2317.DOI:10.1158/1541-7786.MCR-19-0461.
[5] John A, Robador JR, Vidal-Y-Sy S, et al. Urothelial carcinoma of the bladder induces endothelial cell activation and hypercoagulation[J].Mol Cancer Res,2020,18(7):1099-1109.DOI:10.1158/1541-7786.MCR-19-1041.
[6] Ramos JD, Wingate JT, Gulati R, et al. Venous thromboembolism risk in patients with locoregional urothelial tract tumors[J].Clin Genitourin Cancer,2017,16(1):e161-e167.DOI:10.1016/j.clgc.2017.08.001.
[7] Sankiewicz A, Guszcz T, Mena-Hortelano R, et al. Podoplanin serum and urine concentration in transitional bladder cancer[J].Cancer Biomark,2016,16(3):343-350.DOI:10.3233/CBM-160572.
[8] Herzog BH, Fu J, Wilson SJ, et al. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2[J].Nature,2013,502(7469):105-109.DOI:10.1038/nature12501.
[9] Takagi S, Oh-hara T, Sato S, et al. Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis[J].Int J Cancer,2014,134(11):2605-2614.DOI:10.1002/ijc.28602.
[10] Tikkinen KAO, Craigie S, Agarwal A, et al. Procedure-specific risks of thrombosis and bleeding in urological non-cancer surgery: systematic review and meta-analysis[J].Eur Urol,2018,73(2):236-241.DOI:10.1016/j.eururo.2017.02.025.
[11] Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis[J].Blood,2013,122(10):1712-1723.DOI:10.1182/blood-2013-04- 460121.
[12] Alevizopoulos A, Tyritzis S, Leotsakos I, et al. Role of coagulation factors in urological malignancy: a prospective, controlled study on prostate, renal and bladder cancer[J].Int J Urol,2017,24(2):130-136.DOI:10.1111/iju.13271.
[13] Abdullah O, Parashar D, Mustafa IJ, et al. Venous thromboembolism rate in patients with bladder cancer according to the type of treatment: A systematic review[J].Cureus,2022,14(3):e22945.DOI:10.7759/cureus.22945.
[14] Wang JK, Boorjian SA, Frank I, et al. Non-O blood type is associated with an increased risk of venous thromboembolism after radical cystectomy[J].Urology,2014,83(1):140-145.DOI:10.1016/j.urology.2013.08.046.
[15] Khorana AA, Dalal M, Lin J, et al. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States[J]. Cancer,2013,119(3):648-655.DOI:10.1002/cncr.27772.
[16] Balan D, Vartolomei MD, Magdás A, et al. Inflammatory markers and thromboembolic risk in patients with non-muscle-invasive bladder cancer[J].J Clin Med,2021,10(22):5270.DOI:10.3390/jcm10225270.
[17] Hussain M, Daignault S, Agarwal N, et al. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma[J]. Cancer,2014,120(17):2684-2693.DOI:10.1002/cncr.28767.
[18] Elsayed AS, Ozair S, Iqbal U, et al. Prevalence and predictors of venous thromboembolism after robot-assisted radical cystectomy[J].Urology,2021,149:146-153.DOI:10.1016/j.urology.2020.11.014.
[19] Pariser JJ, Pearce SM, Anderson BB, et al. Extended duration enoxaparin decreases the rate of venous thromboembolic events after radical cystectomy compared to tnpatient only subcutaneous heparin[J].J Urol,2017,197(2):302-307.DOI:10.1016/j.juro.2016. 08.090.
[20] Fantony JJ, Gopalakrishna A, Noord MV, et al. Reporting bias leading to discordant venous thromboembolism rates in the United States Versus Non-US Countries following radical cystectomy: A systematic review and meta-analysis[J].Eur Urol Focus,2016,2(2):189-196.DOI:10.1016/j.euf.2015.09.003.
[21] Gao J, Shi Y, Zhou D, et al. Sarcopenia as an independent predictor for venous thromboembolism events in bladder cancer patients undergoing radical cystectomy[J].Support Care Cancer,2022,30(2):1191-1198.DOI:10.1007/s00520-021-06423-2.
[22] Amenyogbe A, Lemire F, Yachnin D, et al. A survey of physician perception and practices regarding pharmacological thromboprophylaxis during chemotherapy for bladder cancer[J].Can Urol Assoc J,2022,16(10):365-370.DOI:10.5489/cuaj.7865.
[23] McAlpine K, Breau RH, Mallick R, et al. Current guidelines do not sufficiently discriminate venous thromboembolism risk in urology[J].Urol Oncol,2017,35(7):457.e1-457.e8.DOI:10.1016/j.urolonc.2017.01.015.
[24] Schomburg J, Krishna S, Soubra A, et al. Extended outpatient chemoprophylaxis reduces venous thromboembolism after radical cystectomy[J].Urol Oncol,2018,36(2):77.e9-77.e13.DOI:10.1016/j.urolonc.2017. 09.029.
[25] Dall CP, Shaw N, Egan J, et al. Practice patterns for extended venous thromboembolism chemoprophylaxis among urologic oncologists after radical cystectomy[J].Urol Oncol,2020,38(11):849.e19-849.e23.DOI:10.1016/j.urolonc.2020.05.030.
[26] Najjar PA, Madenci AL, Zogg CK, et al. Implementation of a comprehensive post-discharge venous thromboembolism prophylaxis program for abdominal and pelvic surgery patients[J].J Am Coll Surg,2016,223(6):804-813.DOI:10.1016/j.jamcollsurg.2016.09.010.
[27] Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update[J].J Clin Oncol,2020,38(5):496-520.DOI:10.1200/JCO.19.01461.
[28] Garas SN, McAlpine K, Ross J, et al. Venous thromboembolism risk in patients receiving neoadjuvant chemotherapy for bladder cancer[J].Urol Oncol,2022,40(8):381.e1-381.e7.DOI:10.1016/j.urolonc.2022.04.006.
[29] Di Nisio M, Candeloro M, Rutjes AWS, et al. Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis[J].J Thromb Haemost,2018,16(7):1336-1346.DOI:10.1111/jth.14149.
[30] Rydell H, Huge Y, Eriksson V, et al. Central venous access and the risk for thromboembolic events in patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer[J].Life (Basel),2022,12(8):1198.DOI:10.3390/life12081198.
[31] Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management[J].Thromb Haemost,2017,117(2):219-230.DOI:10.1160/TH16-08-0615.
[32] Tully CM, Apolo AB, Zabor EC, et al. The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents[J].Cancer,2016,122(5):712-721.DOI:10.1002/cncr.29801.
[33] Chen Y, Lei H, Wang W, et al. Characteristics and predictors of venous thromboembolism among lymphoma patients undergoing chemotherapy: a cohort study in China[J].Front Pharmacol,2022,13:901887.DOI:10.3389/fphar.2022.901887.
[34] 王婉渔. 妇科手术患者应用静脉血栓栓塞症危险因素评估评分简表的护理价值[J]. 国际医药卫生导报,2020,26(22):3503-3506.DOI:10.3760/cma.j.issn.1007-1245.2020. 22.043.

预防膀胱癌患者发生静脉血栓栓塞的研究进展

Advances on prevention of venous thromboembolism in patients with bladder cancer

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	刘玉姣王超刘菲. 中西医结合治疗产后盆底肌筋膜疼痛的研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1204-1207.
[2]	王泽川黄月琴. 急性髓系白血病靶向药物治疗新进展 [J]. 国际医药卫生导报, 2023, 29(8): 1045-1048.
[3]	徐仕杰罗泽斌陈晓东. CT肺动脉成像在肺栓塞诊治中的应用进展 [J]. 国际医药卫生导报, 2023, 29(8): 1053-1056.
[4]	张衡潘广涛殷鸣张平尹霞. 自体脂肪移植在整形外科中的研究进展 [J]. 国际医药卫生导报, 2023, 29(7): 889-892.
[5]	吴雪梅张玉杰解胜华. 银屑病与心血管共病关系的研究进展 [J]. 国际医药卫生导报, 2023, 29(4): 453-456.
[6]	杨丽娜王玉夏铂. 烙灸临床应用研究进展 [J]. 国际医药卫生导报, 2023, 29(2): 154-.
[7]	张翠刘振刘婧扬石新烨刘志强孙经武. NLRP3炎性小体与糖尿病心肌病的研究进展 [J]. 国际医药卫生导报, 2023, 29(16): 2221-2225.
[8]	方建锋. 肠道菌群与代谢性疾病关系研究进展 [J]. 国际医药卫生导报, 2023, 29(16): 2225-2229.
[9]	龙玲美刘伟旺伍媛. 骨质疏松及骨折风险危险因素和评估工具的应用 [J]. 国际医药卫生导报, 2023, 29(16): 2230-2234.
[10]	赵嘉昊商雪祝慧李昕玺徐会圃. PI3K/AKT信号通路在心血管疾病中的研究进展 [J]. 国际医药卫生导报, 2023, 29(15): 2077-2080.
[11]	董金玉龚星源马跃胡忠波刘晟刘永良. 二甲双胍在脊髓损伤中的实验性研究进展 [J]. 国际医药卫生导报, 2023, 29(15): 2081-2085.
[12]	孙虓刘成霞王娜郝佳慧储琳琳. 电针刺激治疗败血症及其相关疾病的研究进展 [J]. 国际医药卫生导报, 2023, 29(15): 2086-2090.
[13]	刘瀛张磊磊. 凶险性前置胎盘诊治进展 [J]. 国际医药卫生导报, 2023, 29(15): 2091-2095.
[14]	陈嘉瑶陈诗雁欧阳良艳祝志敏陈菲邱少东. 斑点追踪技术在评估主动脉瓣狭窄患者左心室功能中的临床应用价值 [J]. 国际医药卫生导报, 2023, 29(14): 1936-1939.
[15]	李振连康小玲李辉斌廖燕霞彭大云郜红艺. 骨唾液酸蛋白在恶性肿瘤中的研究进展 [J]. 国际医药卫生导报, 2023, 29(14): 1940-1943.